Clinical Trial

Biocure Technology Inc. Enters into Exclusive Letter Agreement to Acquire Atriva Therapeutics GmbH in Reverse Takeover Transaction

Vancouver, British Columbia--(Newsfile Corp. - September 18, 2023) - Biocure Technology Inc. (CSE: CURE) ("CURE" or the "Company") announces that…

1 year ago

FloraWorks Announces Updated Analysis of Landmark Clinical Trial; CBN Shown Effective for Sleep

Radicle Science found TruCBN(TM) to significantly improve sleep outcomes in first-ever placebo-controlled trial of pure CBNPortland, Oregon--(Newsfile Corp. - September…

1 year ago

Oncocyte’s VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier

Interventional study compares VitaGraft to current transplant rejection monitoring protocolsOncocyte's VitaGraft assay detects antibody-mediated transplant rejection 10 months sooner than…

1 year ago

FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis; The Report Shows Compound to be Safe and Well Tolerated

TORONTO, ON / ACCESSWIRE / September 18, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical…

1 year ago

Ainos’ VELDONA Granted Orphan Drug Designation by U.S. FDA for Potential Treatment of Oral Warts in HIV-Seropositive Patients

VELDONA® positioned as a potential treatment option for over 24,000 HIV-seropositive AmericansSAN DIEGO, CA / ACCESSWIRE / September 18, 2023…

1 year ago

LAPIX Therapeutics Inc. Announces FDA Clearance of IND Application for its Treg-expanding Tim3/4 Agonist LPX-TI641 to Treat Multiple Sclerosis

BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- LAPIX Therapeutics, Inc. (“LAPIX”), a biopharmaceutical company focused on developing novel, orally bioavailable…

1 year ago

Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company

AI-powered target discovery for a bacterial pathogen with a high medical need where no vaccine is currently available Evaxion’s proprietary AI-platforms…

1 year ago

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

- Topline results from this study are expected in early Q1 2024 - Celltrion has a right of first negotiation…

1 year ago

TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned

Full ENVASARC accrual expected in Q4 and final data expected in mid-2024SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- TRACON…

1 year ago

Ambrx to Participate in the Cantor Fitzgerald Global Healthcare Conference

Morgan Stanley Fireside Chat Replay Now AvailableSAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., Ambrx (or the…

1 year ago